Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG401 vs physician’s choice chemotherapy as first-line therapy in unresectable locally recurrent or metastatic triple-negative breast cancer
CTR20251280Phase 3Suspended
- Sponsor
- Affinity Biopharma
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ESG401 in triple-negative breast cancer (TNBC), sponsored by Affinity Biopharma. Started Sep 2025; status: suspended.
02
Drugs
ESG401
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20251280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251280.